Меню
Идёт набор NCT07483879

Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes

Наблюдательное Type 1 Diabetes Mellitus Diabetic Ketoacidosis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Biomarker and Echocardiographic Assessment.
Кому может быть актуально
Состояния в реестре: Type 1 Diabetes Mellitus, Diabetic Ketoacidosis. Базовые параметры: 2 лет — 16 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Греция
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Evaluation of Biomarkers and Clinical Parameters of Acute Organ Injury in Children With Newly Diagnosed Type 1 Diabetes: The Effect of Diabetic Ketoacidosis

Обзор

Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart. Early detection of organ dysfunction is important for identifying children at increased risk for complications. This observational cross-sectional study aims to evaluate biomarkers of acute organ injury and associated clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls. Biomarkers including KIM-1, NGAL, high-sensitivity troponin, NT-proBNP, interleukin-6, and C-reactive protein will be measured during hospital admission and within the first 24-48 hours of hospitalization.

Подробное описание

Diabetic ketoacidosis (DKA) is a common and potentially life-threatening metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM). In addition to the acute metabolic disturbances, DKA may lead to early or subclinical injury of vital organs, particularly the kidneys and the cardiovascular system, due to dehydration, hypovolemia, metabolic acidosis, electrolyte disturbances, and inflammatory activation.

Recent studies suggest that novel biomarkers may allow early detection of organ dysfunction before conventional clinical indicators become abnormal. Biomarkers such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, high-sensitivity troponin (hs-troponin), and N-terminal pro-B-type natriuretic peptide (NT-proBNP) have been proposed as sensitive indicators of kidney and myocardial injury. Inflammatory markers such as interleukin-6 (IL-6) and C-reactive protein (CRP) may also reflect systemic inflammatory activation associated with metabolic decompensation.

The aim of this observational cross-sectional study is to investigate and compare biomarkers of acute organ injury and related clinical and echocardiographic parameters in children with newly diagnosed T1DM presenting with DKA, compared with children with newly diagnosed T1DM without DKA and healthy controls.

Participants will be categorized into three groups: (1) children with newly diagnosed T1DM presenting with DKA, (2) children with newly diagnosed T1DM without DKA, and (3) healthy children serving as controls. Blood samples will be collected at hospital admission for measurement of biomarkers including KIM-1, NGAL, hs-troponin, NT-proBNP, IL-6, and CRP, as well as standard laboratory parameters such as serum creatinine, cystatin C, albuminuria, pH, bicarbonate levels, and HbA1c.

All participants with T1DM will undergo cardiological evaluation including clinical examination, electrocardiogram, and transthoracic echocardiography with conventional measurements as well as advanced techniques such as tissue Doppler imaging and speckle-tracking echocardiography. Data collection will be performed at admission and within the first 24-48 hours of hospitalization.

The primary objective of the study is to compare biomarker levels and clinical parameters among the three study groups in order to identify early evidence of acute or subclinical organ dysfunction associated with diabetic ketoacidosis in children with newly diagnosed T1DM.

Вмешательства

  • Диагностический тест Biomarker and Echocardiographic Assessment
    Blood and urine samples and echocardiographic evaluation performed as part of the clinical assessment of children with newly diagnosed type 1 diabetes.

Первичные конечные точки

  • Neutrophil Gelatinase-Associated Lipocalin [Срок оценки: Within 48 hours of hospitalization]
  • Kidney Injury Molecule-1 [Срок оценки: Within 48 hours of hospitalization]
  • High-Sensitivity Troponin [Срок оценки: Within 48 hours of hospitalization]
  • N-terminal pro-B-type Natriuretic Peptide [Срок оценки: Within 48 hours of hospitalization]
  • Interleukin-6 [Срок оценки: Within 48 hours of hospitalization]
  • C-reactive Protein [Срок оценки: Within 48 hours of hospitalization]
Вторичные конечные точки (11)
  • Serum Creatinine [Срок оценки: Within 48 hours of hospitalization]
  • Cystatin C [Срок оценки: Within 48 hours of hospitalization]
  • Left Ventricular Ejection Fraction [Срок оценки: Within 48 hours of hospitalization]
  • Left Ventricular Fractional Shortening [Срок оценки: Within 48 hours of hospitalization]
  • E/e' Ratio [Срок оценки: Within 48 hours of hospitalization]
  • Left Ventricular Global Longitudinal Strain [Срок оценки: Within 48 hours of hospitalization]
  • Glutamic Acid Decarboxylase Antibodies (GAD65) [Срок оценки: Within 48 hours of hospitalization]
  • Insulin Autoantibodies (IAA) [Срок оценки: Within 48 hours of hospitalization]
  • Islet Antigen-2 Antibodies (IA-2) [Срок оценки: Within 48 hours of hospitalization]
  • Zinc Transporter 8 Antibodies (ZnT8) [Срок оценки: Within 48 hours of hospitalization]
  • Severity of Diabetic Ketoacidosis [Срок оценки: Baseline]

Критерии участия

Критерии включения

  • Children aged 2-16 years
  • Newly diagnosed type 1 diabetes mellitus
  • Hospital admission for initial evaluation and treatment
  • Presence or absence of diabetic ketoacidosis at diagnosis
  • Written informed consent from parents or legal guardians

For control group:

\- Age-matched healthy children without diabetes

Критерии исключения

  • Previous diagnosis of diabetes mellitus
  • Known chronic kidney disease
  • Known cardiovascular disease
  • Acute infection or inflammatory condition unrelated to diabetes
  • Use of medications that may affect renal or cardiac biomarkers

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Модель наблюдения
Случай-контроль

Центры проведения

Греция · 1 центр
  • Hippokration General Hospital of Thessaloniki — Thessaloniki

Идентификаторы

NCT: NCT07483879 · AUTH-AC-3

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗